CIRCADIAN BLOOD PRESSURE PROFILE AND DIFFERENT DIURETIC THERAPY REGIMENS IN PATIENTS WITH SEVERE CHRONIC HEART FAILURE: EFFECTS ON NATRIURETIC PEPTIDE LEVELS

Arterial hypotension, including orthostatic hypotension, is associated with cardiovascular morbidity and mortality risk in elderly patients. However, the prognostic role of orthostatic hypotension in chronic heart failure (CHF) is under-studied. This study aimed at comparing torasemide and furosemide effects on 24-hour blood pressure (BP) profile, BP level in orthostatic test, and brain natriuretic peptide (BNUP) level dynamics in patients with functional class (FC) III-IV CHF. The study included 40 patients with stable FC III-IV CHF and left ventricular ejection fraction (LVEF) <40% (Simpson); 90≤systolic BP≤140 mm Hg. Dynamics of clinical status, 6-minute walk test results, BNUP and aldosterone levels, quality of life (QoL), 24-hour BP monitoring (BPM), and active orthostatic test (OT) results was also assessed. All participants were randomised into two groups: one group (n=20) received torasemide (TG), and another group (n=20) was administered furosemide (FG). In patients with lower BP levels during 24-hour BPM and OT, higher levels of BNUP were registered. Lower BP levels affected the titration of the doses recommended for CHF treatment. In both groups, reduced CHF FC, decreased blood BNUP levels, and increased distance in a 6-minute walk test were observed. However, TG demonstrated higher BP levels and smaller BP drop in OT, which allowed using higher doses of beta-adrenoblockers (BAB) and increased QoL significantly. In patients with severe systolic CHF and substantial BP drop in OT, BNUP levels were higher. Switching from furosemide to torasemide helped to reduce orthostatic reaction, to optimise circadian BP profile, and to increase BAB doses in patients with Stable FC III-IV CHF.

Arterial hypotension, orthostatic hypotension, chronic heart failure, diuretics

1. Task Force on Heart Failure of the European Society of Cardiology: Guidelines for the diagnosis of heart failure. Eur Heart J 1995; 16: 741-51.

2. Heart Failure Society of America (HFSA) Practice Guildelines. HFSA Guidelines for Management of Patients With Heart Failure Caused by Left Ventricular Systolic Dysfunction – Pharmacological Approaches. p.1-36.

3. Cleland J.G., Gemmell I, Khand A. et al. Is the prognosis of heart failure improving? Eur J Heart Fail 1999; 1:229-241.

4. Трукшина М.А., Ситникова М.Ю., Краснова О.А., Иванов С.Г. Динамика структурно-функциональных показателей миокарда, повреждения эндотелия и состояния ХСН и вторичной легочной гипертензии при лечении карведилолом. Клиническая фармакология и терапия, 2008; 17 (1). С 30-34.

5. Федотов П.А., Ситникова М.Ю., Шапорова Н.Л., Нестерова И.В. Особенности течения сердечной недостаточности при сочетании с хронической обструктивной болезнью легких. Возможности комбинированной терапии, включающей кардиоселективный β1 -адреноблокатор небиволол. Кардиология СНГ Том 4 №1, с. 62-67.

6. Федотов П.А., Ситникова М.Ю., Шапорова Н.Л., Трофимов В.И. Особенности течения сердечной недостаточности при сочетании с хронической обструктивной болезнью легких. Возможности комбинированной терапии, включающей кардиоселективный β1 -адреноблокатор небиволол. Ученые записки. 10.2007.

7. Rita Moretti, Paola Torre, Rodolfo M Antonello et al. Risk factors for vascular dementia: Hypotension as a key point. Vascular Health and Risk Management 2008: 4(2) 395-402

8. GEORGE MAK et al. Multiple Neurohormonal Modulating Agents in Systolic Dysfunction Heart Failure: Are We Lowering Blood Pressure Too Much? Journal of Cardiac Failure Vol.14 No 7 2008)

9. Staessen J.A., Bieniaszewski L., O’Brien E.T., Imai Y., Fagard R. An epidemiological approach to ambulatory blood pressure monitoring: the Belgium population study. Blood Press Monit 1996; 1: 13-26.

10. Vinay Thohan, William C. Little. Is a higher blood pressure better in heart failure. Heart Online First, Oct 31, 2008. http://heart.bmj. com/cgi/content/abstract/hrt.2008.151779v1

11. Goyal D, MacFadyen RJ, Watson RD, Lip GY. Ambulatory blood pressure monitoring in heart failure: a systematic review. Eur J Heart Fail.2005;7:149-56.

12. Jaekyu Shin, PharmD, Sharoen Kline et al. Assotiation of Diurnal Blood Pressure Pattern With Risk of Hospitalisation or Death in Men With eart Failure. Journal of Cardiac Failure Vol.13 No 8 2007

13. The Consensus Committee of the American Autonomic Society and the American Academy of neurology. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. Neurology. 1996; 46: 1470.

14. Rose K.M., Tyroler H.A., Nardo C.J. et al. Orthostatic hypotension and the incidence of coronary heart disease: the Aterosclerosis Risk in Communities Study. Am J Hypertens. 2000; 13:571-578.

15. Eigenbrodt M.L., Rose KM, Couper DJ et al. Orthostatic hypotension as a risk factor for stroke: the Aterosclerosis Risk in Communities (ARIC) Study, 1987-1996. Stroke. 2000; 31: 2307-2313.

16. Masaki K.H., Schats I.J., Burchfiel C.M. et al. Orthostatic hypotension Predicts mortality in eldery men: the Honolulu Heart Program. Circulation. 1998; 98: 2290-2295.

17. Luukinen H., Koski K., Laippala P., Kivela S.L. Prognosis of diastolic and systolic orthostatic hypotension in older persons. Arch Intern Med. 1999; 159:273-280.

18. Yamamoto K., Burnett J., Jougasaki M. et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension, 1996, 28, 988-994.

19. Richards A., Troughton R., Lainchbury J. Guiding and monitoring of heart failure therapy with NT-proBNP: consepts and clinical studies. J. Cardiac Fail., 2005, 11 (5, Suppl.), 34-37

20. Hall C. NT-pro BNP: The mechanism behind the marker. J. Cardiac Fail.< 2005, 11 (5, Suppl.), 81-83.

21. Ситникова М.Ю., Бондаренко Б.Б. Роль почек в патогенезе сердечной недостаточности. Учебное пособие. Под редакцией члена-корреспондента РАМН профессора Шляхто Е.В. Санкт- Петербург. – 1999. – 27c.

22. Davidson N., Struthers A.D. Brain natriuretic peptide //’Journal Hypertens. – 1994. – Vol. 12. – P. 329-336.

23. Jamison R.L., Canaan-Kuhl S., Pratt R. The natriuretic peptides and their receptors // American Journal of Kidney Disease. – 1992. – Vol. 20. – P. 519-530.

24. Martin R. Cowie, Gustavo F.Mendez. BNP and Congestive Heart Failure.Curr Probl Cardiol 2003;44:264-311.

25. Fiedel H., Duckley M. Torsemide. A review of its pharmacological properties and therapeutic potential. Drugs 1991; 41:1:81-103.

26. Bolke T., Achhammer I. Torsemide: review of its pharmacology and therapeutic use. Drugs today 1994;30:1-28.

27. Yamamoto M., Sasakki T., Honda K. et al. Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure. Circ. J.,2003, 67 (5), 384-390.